Clinical Trial Update: Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study [Phase 2]

View source ↗

Summary

A Phase II trial evaluating disitamab vedotin with bevacizumab for HER2-low metastatic breast cancer after failure of T-DXd, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: HER2-low Breast Cancer | Phase 2 | Status: RECRUITING